MEDI4736 and Tremelimumab for Patients with Hepatocellular Carcinoma - Clinical Trial
What is the Purpose of this Study?
Who Can Participate in the Study?
- Have never had treatment with drugs similar to durvalumab, tremelimumab, or bevacizumab
- Have a body weight of at least 66 pounds
- Have hepatocellular carcinoma
What is Involved?
If you choose to join this study, you will receive a combination of the study drugs durvalumab and bevacizumab until your cancer gets worse or the study doctor decides to take you off the study.